Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | PPARG | P37231 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.49 |
| ▸ | APLNR | P35414 | 3/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712581 | 0.92 | MEN1 (0.77) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL14351071 | 0.92 | MEN1 (0.68) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL19661356 | 0.92 | MEN1 (0.68) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL13232606 | 0.92 | MEN1 (0.68) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL1083752 | 0.92 | MEN1 (0.68) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL1083748 | 0.92 | MEN1 (0.74) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29569925 | 0.91 | MEN1 (0.79) | MEN1USP2POLBPPARGBLM | |
| Water SCHEMBL185914 | 0.91 | MEN1 (0.76) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL17267894 | 0.91 | MEN1 (0.76) | MEN1USP2POLBPPARGBLM | |
| Water SCHEMBL3843902 | 0.91 | MEN1 (0.67) | MEN1USP2POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | MEN1 3725/4885USP2 863/4885POLB 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.